



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket: EIS-SCHWARTZ=2

In re Application of:)	Conf. No.: 4767
)	
EISENBACH-SCHWARTZ et al)	Art Unit: 1647
)	
Appln. No.: 09/314,161)	Examiner: S. Turner
)	
Filed: May 19, 1999)	Washington, D.C.
)	
For: ACTIVATED T-CELLS, NERVOUS))	December 30, 2002
SYSTEM-SPECIFIC ANTIGENS))	
AND THEIR USES))	

#19
M.G.J
1/7/03

DECLARATION

Honorable Commissioner for Patents
Washington, D.C. 20231

Sir:

I, the undersigned Michal Eisenbach-Schwartz, hereby
declare and state as follows:

1. I am an inventor in the above-identified
application.
2. My curriculum vitae is attached hereto as
Exhibit A.
3. I am aware that the examiner has criticized the
above-identified application as claiming the use of T-cells
activated by any nervous system specific antigen but having
examples only for T-cells activated with MBP.
4. Attached hereto as Exhibit B is a publication
of Hauben et al, of which I am co-author, entitled

"Vaccination with a Nogo-A-derived peptide after incomplete spinal-cord injury promotes recovery via a T-cell-mediated neuroprotective response: Comparison with other myelin antigens", which was published at PNAS 98:15173-15178 (2001).

5. All of the experiments described in the publication attached as Exhibit B were conducted either by me or under my supervision. Accordingly, I hereby state of my own knowledge that all of the experiments and the experimental results described therein are true and correct.

6. Reference is particularly made to the experiment bridging columns 1 and 2 of page 15176 establishing that T-cells directed against Nogo-A-derived peptide are neuroprotective when passively transferred into SPD rats. This confirms what would have been expected from the results obtained by actively vaccinating with Nogo-A derived peptide previously described in the publication.

7. Example 8.2 in the above-identified specification refers to administration of MOG which causes NS-specific activated T-cells to accumulate at the site of injury. While we did not do the concomitant experiment of passive vaccination with the MOG activated T-cells, the results with MBP and Nogo-A establish that the results achieved with active vaccination are also obtained when using the corresponding passive vaccination. Thus, one of ordinary

skill in the art would believe that the results obtained by active vaccination of MOG would be the same if passive vaccination with MOG activated T-cells had been conducted.

8. Accordingly, three examples are of record establishing that vaccination with T-cells activated by three different NS-specific antigens are all successful or expected to be successful in reducing neurodegeneration. Accordingly, it is reasonable to conclude that T-cells activated by any NS-specific antigen can also be operable for the reasons detailed in the above-identified specification.

I hereby further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

29.12.2002.
Date

Michael S. D.

CURRICULUM VITAE

Personal Details

Full Name: Michal Schwartz
Place of Birth: Tel Aviv, Israel
Marital Status: Married; four children

Education and Research Experience

- 1968–1971 B.Sc. in Chemistry, The Hebrew University of Jerusalem, Israel.
- 1972–1977 Ph.D. in Chemical Immunology, Department of Chemical Immunology, The Weizmann Institute of Science, Rehovot, Israel.
Thesis: The molecular and cellular basis of the genetic control of the immune response to newly synthesized ordered polypeptides. Supervisors: Profs. M. Sela and E. Mozes.
- 1977–1978 Postdoctoral Fellow, Department of Chemical Immunology, The Weizmann Institute of Science.
Research subject: Neuroimmunology - Immunological aspects of myasthenia gravis, in collaboration with Prof. S. Fuchs.
- 1978–1980 Postdoctoral fellow, Prof. B. Agranoff's Laboratory, Department of Neuroscience, University of Michigan, Ann Arbor, MI, USA.
Research subject: Biochemical aspects of nerve regeneration.
- 1980–1985 Senior Scientist, Department of Neurobiology, The Weizmann Institute of Science.
- 1985–1998 Associate professor with tenure, Department of Neurobiology, The Weizmann Institute of Science.
- 1987– Maurice and Ilse Katz Professorial Chair in Neuroimmunology.
- 1988–1992 Visiting Associate Professor, Department of Anatomy, Medical College of Pennsylvania, PA, USA.
- 1996 Founded a start-up company (Proneuron Biotechnologies)
- 1998 Professor, Department of Neurobiology, The Weizmann Institute of Science, Rehovot, Israel

Honors and Prizes

- 1970 B'nei-Brith Prize for Distinguished Students
(awarded by the Hebrew University of Jerusalem).
- 1971 Prize for Distinguished B.Sc. Students
(awarded by the Hebrew University of Jerusalem).

- 1977 Landau Prize for Distinguished Ph.D. Students
(awarded by the Feinberg Graduate School,
The Weizmann Institute of Science).
- 1978–1980 Chaim Weizmann Award for Postdoctoral Training.
- 1981–1985 The Helena Rubinstein Career Development Chair.
1985 Prof. Stein Prize for Distinguished Work on the Visual System
(awarded by Tel Aviv University).
- 2002 International Award in Ophthalmology, Singapore.
- 1996 Glaucoma Foundation Award.
- 1997 Alcon Award for Outstanding Contribution in Eye Research.
- 1998 Academia Ophthalmologica Internationalis Award
for “Skilled Scientist and Eminent Teacher”, June 1998.
- 2000 Career Woman of the year 2000, Israel
- 2001 The 22nd Annual Peter and Eva Safar Annual Lectureship in Medical
Sciences and Humanities, University of Pittsburgh, school of Medicine.
- 2002 ARVO Award for outstanding research in the basic or clinical sciences as
applied to ophthalmology (Friedenwald Award).
- 2002 The G. Heiner Sell Memorial Lectureship for outstanding achievement in the
field of spinal cord injury, awarded by the American Spinal Cord Injury
Association.
- 2002 The Post-Polio Research Award
- 2002 The IGR Award

Scientific Advisory Boards

- 1994 – The Glaucoma Foundation, USA
- 2003 TEVA Ltd. Ad hoc member for Central Nervous System Research
- 1993– Member of the scientific advisory board for neuroprotection, Allergan Ltd
- 1997-1999 Biomedics Investments, Israel
- 1998-2000 Elected Member in The International Committee of Association for
Research in Vision and Ophthalmology (ARVO).
- 1999– Member of Medical Advisory Board,
The Alan T. Brown Foundation to Cure Paralysis.

2000— Elected Member of The Scientific Board of
The International Society of Neuroimmunomodulation

Editorial Boards

Neuroscience Research Communications (1990 -)

Journal of Restorative Neurology and Neuroscience (1995 -

Journal of Molecular Neuroscience, (2001 -)

Investigative Ophthalmology and Visual Sciences (2001 –)

Honorary and Invited Lectures presented at Symposia and Conferences Since 1990

1. 6th International Symposium on Development, Transplantation and Plasticity of the Nervous System. September, 1990.
2. European Association of Neurological Societies: European Course on Neurosurgery. Jerusalem, Israel, September, 1990.
3. 3rd International Conference on Tumor Necrosis Factors and Related Cytokines. Tokyo, Japan, November, 1990.
4. 4th Otto Loewi Center Meeting on Development and Functioning of Neuronal Networks. Jerusalem, Israel, April, 1991.
5. Regional Meeting on Physiological Sciences. Prague, Czechoslovakia, June, 1991.
6. Rockefeller University – The Weizmann Institute of Science Symposium on Neuronal Plasticity. Rehovot, Israel, October, 1991.
7. International Society of Neuroimmunology: 3rd International Congress (**plenary lecturer**), Jerusalem, Israel, October, 1991.
8. 2nd International Symposium on Ocular Trauma. Geneva, Switzerland, April 2–5, 1992.
9. International Symposium on Eye Research. Stressa, Italy, September, 1992.
10. Satellite Symposium of the European Neuroscience Association on Stimulation of Brain Repair. Munich, Germany, September, 1992.
11. Philippe Laudat Conference on Cytokines and the Brain. Le Bischenberg, France, October, 1992.
12. Taniguchi Foundation Symposium on Development and Function in the Visual System. Katata, Japan, November, 1992.
13. International Symposium on Low-Energy Laser Biostimulation. Los Angeles, CA, USA, January, 1993.
14. Fifth International Symposium on Neural Regeneration. Asilomar, CA, USA, December, 1993.

15. FASEB Summer Conference on Interactions of the Nervous and Immune Systems: Peptides, Neurotransmitters, Cytokines, Adhesion Molecules and their Receptors. Copper Mountain, CO, USA, July, 1994.
16. Fourth International Conference on Transglutaminases and Protein Cross-Linking Reactions. Budapest, Hungary, August, 1994.
17. European Society for Neuroscience: Workshop on the Cross Talk between the Immune and the Nervous Systems. August, 1994.
18. Fifteenth Annual Meeting of the Israel Society for Eye and Vision Research (**honorary guest lecturer**). Israel, December, 1994.
19. International Symposium on Low-Energy Laser Biostimulation. Los Angeles, CA, USA, January, 1995.
20. 2nd Annual Think Tank on Optic Nerve Regeneration. Glaucoma Foundation, New York, NY, USA, May, 1995.
21. 9th International Congress of Immunology. San Francisco, CA, USA, July, 1995.
22. International Symposium on Experimental and Clinical Ocular Pharmacology and Pharmaceutics. Geneva, Switzerland, September, 1995.
23. 11th European Congress on Multiple Sclerosis. Jerusalem, Israel, September, 1995.
24. Leading Scientists Meeting on Glaucoma. Tempe, AZ, USA, March, 1996.
25. The 3rd Annual Think Tank on Optic Nerve Regeneration. Glaucoma Foundation, New York, NY, USA, May, 1996.
26. Fourth Altschul Symposium on Cell Biology and Pathology of Myelin: Evolving Biological Concepts and Therapeutic Approaches. Saskatoon, Canada, June, 1996.
27. CNS Regeneration Conference. University of Kentucky, Lexington, KY, USA, June, 1996.
28. FASEB Summer Conference on Interactions of the Nervous and Immune Systems. Copper Mountain, CO, USA, July, 1996.
29. Amgen Symposium on Trophic Factors in Glaucoma. San Diego, CA, USA, July, 1996.

30. International Symposium on Experimental Spinal Cord Repair and Regeneration. Brescia, Italy, October, 1996.
31. Winter Glaucoma School. The Grand Cayman. February, 1997.
32. Symposium on Neuroprotection and Apoptosis. Uppsala, Sweden, April, 1997.
33. First Annual Conference in Association with Vision Research, Molecular, Cellular and Genetic Approaches to Function and Dysfunction of the Retina. Fort Lauderdale, FL, USA, May, 1997.
34. Association for Research in Vision and Ophthalmology (ARVO) Symposium on Neuroprotection in Glaucoma. Fort Lauderdale, FL, USA, May, 1997.
35. New Horizons in Neuroimmunology, 9th Rappaport Symposium. Israel, May, 1997.
36. 3rd Meeting of ETRO Working Party on Factor XIII. Eger, Hungary, May, 1997.
37. 4th Think Tank in Glaucoma. New York, NY, USA, June, 1997.
38. XIth Congress of the European Society of Ophthalmology (**guest lecturer**). Hungary, Budapest, June, 1997.
39. International Symposium on Experimental and Clinical Ocular Pharmacology and Pharmaceutics. Munich, Germany, September, 1997.
40. American Academy of Ophthalmology. San Francisco, CA, October, 1997.
41. Neurodegeneration and Neuroprotection in Neurodegenerative diseases. Jerusalem, Israel, November, 1997.
42. International Meeting on Optic Nerve Structure, Function and Neuroprotection, supported by Santen Pharmaceuticals. Portland, OR, USA, November, 1997.
43. Bat-Sheva Seminar on Cellular, Molecular and Genetic Aspects of Aging and Longevity. Israel, December, 1997.
44. 2nd International Glaucoma Symposium. Jerusalem, March, 1998.
45. Joint Minerva-GIF meeting on New Strategies and Perspectives in Understanding CNS Disorders. Jerusalem, May, 1998.

46. Boehringer Ingelheim Symposium on Brain Repair Strategies for the Treatment of Chronic Neurodegenerative Diseases. Germany, May, 1998.
47. Association for Research in Vision and Ophthalmology (ARVO) Symposium on Neuroprotection and Regeneration in Glaucoma (**symposium moderator**). Fort Lauderdale, FL, USA, May, 1998.
48. The Ocular Drug and Surgical Therapy Update. Laguna Niguel, California, June, 1998.
49. International Congress of Academy of Ophthalmology (**Keynote Lecturer**). June, 1998.
50. FASEB Summer Conference on Interaction of the Nervous and the Immune Systems (**elected Conference Chairperson and keynote lecturer**). Copper Mountain, CO, USA, July, 1998.
51. XIII international congress of Eye Research. Paris, July, 1998.
52. International Society of Neuroimmunology. Montreal, August, 1998.
53. The 4th Annual Think Tank on Optic Nerve Regeneration. Glaucoma Foundation, New York, NY, USA, September, 1998.
54. International Symposium on Experimental Spinal Cord Repair and Regeneration. Brescia, Italy, October, 1998.
55. Retinal Ganglion Cell Catalyst. Quebec, October, 1998.
56. Second Joint Meeting of the International Cytokine Society, symposium on Cytokines and Neuroimmunomodulation. Jerusalem, October, 1998.
57. **Invited Teacher** in Tufts Medical School in a "Course on Neurotoxicity and Neuroprotection" (a part of Continuing Education in Medicine). Boston, October, 1998.
58. European Association of Vision and Eye Research (EVER), Symposium on Neuroprotection in Relation to Ischemia and Glaucoma. Palma de Mallorca, October, 1998.
59. Federation of The Israel Societies of Experimental Biology (FISEB), Symposium on Development and Regeneration in the Nervous System. Jerusalem, December, 1998.

60. American Association for the Advancement of Science (AAAS), Symposium on Brain-Immune Connection: From Popular Myth to Hard Science. Anaheim, California, January, 1999.
61. Glaucoma Experts Meeting 1999. St. Moritz, Switzerland, March, 1999.
62. 2nd International Congress of Autoimmunity. Tel Aviv, March, 1999.
63. Alcon Research Institute Symposium, (**Alcon Awardees for Outstanding Contributions in the Field of Vision Research**). Texas, USA, March 1999.
64. Second Spinal Cord Symposium, Paralyzed Veterans of America. Arlington, VA., April, 1999.
65. Association for Research in Vision and Ophthalmology (ARVO), Opening symposium of the 1999 meeting on Neuroprotection and Neuroregeneration. Florida, May, 1999.
66. Frontiers in Spinal Cord Regeneration. 5th Annual Kentucky Spinal Cord and Head Injury Research Trust Symposium. Louisville, June, 1999.
67. Fourth Annual Mayo-Luther forum on Hematopoietic Cells. Mayo Clinic, Rochester, Minnesota, June, 1999.
68. The XIIth Congress of European Society of Ophthalmology, Symposium on Neuroprotection in Glaucoma. Stockholm, June, 1999.
69. Fifth IBRO World Congress of Neuroscience, Symposium on CNS Ischemia and Traumatized neuroprotective approaches. Jerusalem, July, 1999.
70. 4th International Congress of International Society for Neuroimmunomodulation, Lugano, September, 1999.
71. Neural Regeneration Symposium, Asilomar, California, USA, December 1999.
72. The 3rd International symposium on Ocular Pharmacology and Pharmaceutics – ISOPP, (**keynote lecturer**). Lisbon, February, 2000.
73. International symposium on Neuroprotection, (**keynote lecturer**). San Antonio, February, 2000.
74. International Symposium on Experimental Spinal Cord Repair and Regeneration, Brescia, Italy, April, 2000.

75. National Health Institute Workshop. The Role of the Immune System in Spinal Cord Injury. Bethesda, MD, April, 2000.
76. International Neuroimmunology Symposium. The Next Neuroscience Generation. Berlin, Germany, May, 2000.
77. American Association of Immunologists, **(chairperson of ISNIM symposium and lecturer)**. Seattle, May, 2000.
78. Tenth meeting of The European Neurological Society, Jerusalem, June, 2000.
79. New England Eye Center. Neuroprotection in Glaucoma – 2000. Boston, Massachusetts, June, 2000.
80. 2nd Neuroprotection Consensus Meeting: “Neuroprotection: Possibilities in Perspective”. London, UK, June, 2000.
81. FASEB Summer Conference on Interaction of the Nervous and the Immune Systems, **(elected Conference Chairperson)**. July, 2000.
82. 5th International Symposium on Ocular Trauma **(Keynote lecture)**. Montreal, Quebec, Canada, July, 2000.
83. International Seminar. Inflammatory Cytokines and Chemokines in the Context of Extracellular Matrix. Jerusalem, Israel, September, 2000.
84. Frontier in Molecular Basis of Diseases. Conference on Cell Biology of Neuronal Dysfunction, Paris, October, 2000.
85. International Society for Neurotrauma, Xian, China, December, 2000.
86. Research to Prevent Blindness Workshop. Glaucoma: A Novel Neuronal Degeneration? Sarasota, Florida, March, 2001.
87. National Multiple Sclerosis Society. Neuronal Injury in MS and Related Disorders: Mechanisms and Prevention. New Orleans, Louisiana, March, 2001.
88. The American Society of Immunologists **(Plenary lecture)**. Orlando, Florida, April, 2001.
89. European Society of Neuroimmunology **(Plenary lecture)**. Bordeaux, June 2001.
90. European Society of Neuroimmunology. Paris, June 2001.

91. The 8th Annual Glaucoma Foundation Optic Nerve Rescue and Restoration Think Tank: Gene Therapy. New York, New York, July 2001.
92. International Society of Neuroimmunology (**Plenary lecture**). Scotland, September 2001.
93. The 2nd European-American Intensive Course in Clinical and Forensic Genetics. Dubrovnik, Croatia, September 2001.
94. XV International Congress of Eye Research (ICER), Geneva, Switzerland, October 2001.
95. The 3rd Congress of Asian-Oceanic Glaucoma Society (AOGS) (**Plenary lecture**). Seoul, Korea, October 2001.
96. Neurological Congress of Rehabilitation, Dusseldorf, Germany, November 2001.
97. Association Pour La Recherche Sur La Sclerose En Plaques: Immunomodulation and Induction of Tolerance in Multiple Sclerosis. Paris, December 2001.
98. The **Elected Lecturer** of the 22nd Annual Peter and Eva Safar Lecture, University of Pittsburgh, December 2001
99. The Gordon conference on myelin. Ventura, California, February 2002.
100. Workshop on Neuroprotection in Ophthalmology. Rome, Italy, February 2002.
101. 3rd International Congress on Autoimmunity. Geneva, Switzerland, February 2002.
102. Brain Plasticity in Health and Disease, National Institute for Psychobiology in Israel. Tel-Aviv, Israel, March 2002.
103. 4th International Symposium on Experimental Spinal CordRepair and Regeneration. Brescia, Italy, March 2002.
104. Joint meeting of the American Spinal Injury Association and the International Medical Society of Paraplegia (**Keynote lecturer**), Vancouver, Canada, May 2002.
105. Association for Research in Vision and Ophthalmology, (**Keynote Lecturer as Recipient of the Friedenwald Award**), Fort Lauderdale, Florida, May 2002.

106. Vancouver, Canada, May, 2002. An invited guest of the Canadian Congress of Neurological Sciences (**Keynote lecturer**). Canada, June 2002.
107. 7th Annual Think Tank. Glaucoma Foundation, Chicago, IL, USA, July 2002.
108. FASEB meeting on Neuro-immune interactions (**Plenary lecture**). Tucson, AZ, USA, August 2002.
109. 4th International Symposium on Experimental and clinical Neurology (**Plenary lecture**). Slovak Republic, September, 2002.
110. The First Joint Meeting of The National And International Neurotrauma Societies: The Sixth International Neurotrauma Symposium and The 20th Annual National Neurotrauma Society Symposium, (**Plenary lecture**). Tampa, Florida, October, 2002.
111. 10th Annual Meeting of the European Society for Gene Therapy. (**Plenary lecture**). Antibes Juan-les-Pins, France, October 2002.
112. American Glaucoma Society Subspecialty Day for presenting the IGR Award, Orlando, Florida, October, 2002.
113. Congress of the British Society for Neuroimmunology, (**Plenary lecture**). Harrogate, UK, December 2002.
114. Italian Neuroimmunology Society Conference on Autoimmunity and Neurodegeneration, (**Plenary lecture**). Bergamo, Italy, March 2003.
115. 4th International Glaucoma Symposium (**Plenary lecture**), Barcelona, Spain, March, 2003
116. Neuroinflammation and Stroke, Berlin, Germany, March, 2003.
117. 3rd International Magdeburg Conference on Neuroprotection and Neurorepair, (**Plenary lecture**), Magdeburg, Germany, May, 2003.
118. 2nd Mucke Symposium on Neurodegeneration and CNS Repair (**Plenary Lecture**), Dusseldorf, Germany, May, 2003.
119. "Spinal Cord Injury: Conventional and Alternative Approaches", Bourges, France, June, 2003.
120. European Neurological Society Meeting, (**Plenary lecture**) Istanbul, Turkey, June 2003.

121. Kentucky Spinal Cord Injury Research Trust Symposium, Louisville, Kentucky, June, 2003.
122. Baltic Summer School, University of Kiel, Kiel, Germany, August, 2003.
123. 33rd Cambridge Ophthalmological Symposium, Cambridge, United Kingdom, September, 2003.

LIST OF PUBLICATIONS

A. Research Papers

1. Mozes, E., Schwartz, M. and Sela, M. (1974) Antibody responses of inbred mouse strains to ordered tetrapeptides of tyrosine and glutamic acid attached to multichain polyalanine and polyproline. *J. Exp. Med.* 140:349-358.
2. Schwartz, M., Mozes, E. and Sela, M. (1975) The genetic control of the immune response of inbred mouse strains to conjugates of (Tyr-Tyr-Glu-Glu) and (Tyr-Glu-Tyr-Glu) with multichain poly-DL-alanine as compared with the response to the random (T,G)-A-L. *Eur. J. Immunol.* 5:866-871.
3. Cramer, M., Schwartz, M., Mozes, E. and Sela, M. (1976) Reconstitution of genetically regulated responses against random and ordered synthetic polypeptides by methylated bovine serum albumin as analyzed by isoelectric focusing. *Eur. J. Immunol.* 6:618-623.
4. Schwartz, M., Walterbaugh, C., Dorf, M., Cesla, R., Sela, M. and Benacerraf, B. (1976) Determinants of antigenic molecules responsible for genetically controlled regulation of immune responses. *Proc. Natl. Acad. Sci. USA* 73:4184-4186.
5. Schwartz, M., Novick, D., Givol, D. and Fuchs, S. (1978) Induction of anti-idiotypic antibodies by immunization with syngeneic spleen cells educated with acetylcholine receptor. *Nature* 273:543-545.
6. Schwartz, M., Lancet, D., Mozes, E. and Sela, M. (1978) Affinity and avidity of antibodies to the random polymer (T,G)-A-L and related ordered synthetic polypeptide. *Immunochemistry* 15:477-481.
7. Schwartz, M., Lifshitz, R., Givol, D., Mozes, E. and Haimovich, J. (1978) Cross-reactive idiotypic determinants of murine anti-(T,G)-A-L antibodies. *J. Immunol.* 121:421-426.
8. Lifshitz, R., Schwartz, M. and Mozes, E. (1978) Specificity and cross-reactivity of idiotypes of murine antibodies induced by (T,G)-A-L and the (Phe,G)-A-L. *Proc. Natl. Acad. Sci. USA* 75:5118-5121.
9. Schwartz, M., Geiger, B., Hooghe, R.J., Bar-Eli, N., Galily, R., Mozes, E. and Sela, M. (1979) The mode of interaction with macrophages of two ordered synthetic polypeptides which differ in their thymus independency. *Immunology* 35:849-855.
10. Schwartz, M., Lancet, D., Tarrab-Hazdai, R. and Fuchs, S. (1979) Effect of axathioprine on the affinity of antibodies against acetylcholine receptor: Analysis with purified antibodies. *Mol. Immunol.* 16:483-487.
11. Tarrab-Hazdai, R., Schwartz, M. and Fuchs, S. (1979) Immunological memory following immunosuppression of experimental myasthenia gravis with axathioprine. *Immunol. Lett.* 1:101-104.
12. Schwartz, M., Parhami, B., Mozes, E. and Sela, M. (1979) Changes in the specificity of antibodies to random synthetic branched polypeptide in mice tolerant to its ordered analogs. *Proc. Natl. Acad. Sci. USA* 76:5286-5288.
13. Lifshitz, R., Schwartz, M. and Mozes, E. (1980) Specificity of genes controlling the immune responsiveness to (T,G)-A-L and (Phe,G)-A-L. *Immunology* 41:339-346.
14. Lifshitz, R., Schwartz, M. and Mozes, E. (1980) Linkage of murine (T,G)-A-L specific idiotypic determinants to the heavy chain constant region allotypic markers. *Immunogenetics* 11:191-198.
15. Fuchs, S., Bartfeld, D., Eshhar, Z., Feingold, C., Moshly-Rosen, D., Novick, D., Schwartz, M. and Tarrab-Hazdai, R. (1980) Immune regulation of experimental myasthenia gravis. *J. Neurol. Neurosurg. Psychol.* 46:634.

16. **Schwartz, M., Axelrod, D., Feldman, E.L. and Agranoff, B.W.** (1980) Histological localization of binding sites of α -bungarotoxin and antibodies specific to acetylcholine receptor in goldfish optic nerve and tectum. *Brain Res.* 194:171-180.
17. **Schwartz, M., Siegel, G.J., Chen, N. and Agranoff, B.W.** (1980) Goldfish brain (Na⁺, K⁺)-ATPase: Purification of catalytic polypeptide and production of specific antibodies. *J. Neurochem.* 34:1745-1752.
18. **Schwartz, M., Ernst, S.A., Siegel, G.J. and Agranoff, B.W.** (1981) Immunocytochemical localization of (Na⁺, K⁺)-ATPase in the goldfish optic nerve. *J. Neurochem.* 36:107-115.
19. **Schwartz, M. and Agranoff, B.W.** (1981) Multiprocesses emerge from cultured retinal ganglion cells. *Brain Res.* 206:331-339.
20. **Kohsaka, S., Schwartz, M. and Agranoff, B.W.** (1981) Increased activity of ornithine decarboxylase in goldfish following optic nerve crush. *Dev. Brain Res.* 1:391-401.
21. **Schwartz, M., Kohsaka, S. and Agranoff, B.W.** (1981) Ornithine decarboxylase activity in retinal explants of goldfish undergoing optic nerve regeneration. *Dev. Brain Res.* 4:403-415.
22. **Feldman, E.L., Axelrod, D., Schwartz, M., Heacock, A.M. and Agranoff, B.W.** (1981) Studies on the localization of newly added membrane in growing neurites. *J. Neurobiol.* 12:591-598.
23. **Cohen, O., Sela, B.A., Schwartz, M., Eshhar, N. and Cohen, I.R.** (1981) Multiple sclerosis-like disease induced in rabbits by immunization with brain gangliosides. *Isr. J. Med. Sci.* 16:711-714.
24. **Schwartz, M., Vogel, Z. and Kalcheim, C.** (1981) Goldfish brain extract induces aggregation of acetylcholine receptors on cultured myotubes: Increased activity following optic nerve axotomy. *Neurosci. Lett.* 27:165-170.
25. **Schwartz, M., Mizrachi, Y. and Eshhar, N.** (1982) Factors from goldfish brain induce neuritic outgrowth from explanted regenerating retinas. *Dev. Brain Res.* 3:29-35.
26. **Schwartz, M., Mizrachi, Y. and Kimhi, Y.** (1982) Regenerating goldfish retinal explants: Induction and maintenance of neurites by conditioned medium from cells originating in the nervous system. *Dev. Brain Res.* 3:21-28.
27. **Mizrachi, Y. and Schwartz, M.** (1982) Goldfish tectal explants have a growth promoting effect on neurites emerging from co-cultured regenerating retinal explants. *Dev. Brain Res.* 3:502-505.
28. **Schwartz, M., Sela, B. and Eshhar, N.** (1982) Antibodies to gangliosides and myelin autoantigens are produced in mice following sciatic nerve injury. *J. Neurochem.* 38:1192-1195.
29. **Spirman, N., Sela, B. and Schwartz, M.** (1982) Antiganglioside antibodies inhibit neuritic outgrowth from goldfish regenerating retinal explants. *J. Neurochem.* 39:874-877.
30. **Schwartz, M. and Spirman, N.** (1982) Sprouting from chicken embryo dorsal root ganglia induced by nerve growth factor is specifically inhibited by affinity purified antiganglioside antibodies. *Proc. Natl. Acad. Sci. USA* 79:6080-6083.
31. **Konat, G., Hoffner, H., Lev-Ran, V., Cohen, O., Schwartz, M., Cohen, I.R. and Sela, B.A.** (1982) Abnormalities in brain myelin of rabbits with experimental autoimmune multiple sclerosis-like disease induced by immunization to gangliosides. *Acta Neurol. Scand.* 66:568-574.
32. **Mizrachi, Y., Ohry, A., Aviel, A., Rosin, R., Brookes, M.E. and Schwartz, M.** (1983) Systemic humoral factors participating in the course of spinal cord injury. *Paraplegia* 21:287-293.
33. **Aviel, A. and Schwartz, M.** (1983) Sprouting inducing activity of human sera: Low capacity in sera from patients with cranial polyneuropathy. *J. Neurosci. Res.* 9:459-465.

34. Gayer, A. and Schwartz, M. (1983) The use of image analysis for measuring neuritic outgrowth from goldfish regenerating retinal explant. *J. Neurosci. Methods* 7:275-280.
35. Neuman, D., Yerushalmi, A. and Schwartz, M. (1983) Inhibition of nonneuronal cell proliferation in the goldfish visual pathway affects regenerative capacity of the retina. *Brain Res.* 272:237-245.
36. Spirman, N., Sela, B., Gitler, C., Kalef, E. and Schwartz, M. (1984) Regenerative capacity of the goldfish visual system is affected by antibodies specific to ganglioside injected intraocularly. *J. Neuroimmunol.* 6:197-207.
37. Schwartz, M. and Eshhar, N. (1984) Early regenerative responses induced by monoclonal antibodies against a surface glycoprotein of goldfish retinal ganglion cells. *EMBO J.* 3:1287-1293.
38. Sparrow, J.R., McGuinness, C., Schwartz, M. and Grafstein, B. (1984) Antibodies to gangliosides inhibit goldfish optic nerve regeneration *in vivo*. *J. Neurosci. Res.* 12:233-243.
39. Schwartz, M., Fischler, H. and Korenstein, R. (1984) Pulsed electromagnetic fields affect neuritic outgrowth from regenerating goldfish retinas. *Bioelectrochem. Bioenerget.* 12:243-251.
40. Rachailovich, I. and Schwartz, M. (1984) Molecular events associated with increased regenerative capacity of the goldfish retinal ganglion cells following X-irradiation: decreased level of axonal growth inhibitors. *Brain Res.* 306:149-155.
41. Mizrachi, Y., Neuman, D., Sharma, S. and Schwartz, M. (1984) Target-dependent and independent stages in regeneration. *Brain Res.* 322:115-118.
42. Solomon, A., Belkin, M., Hadani, M., Harel, A., Rachailovich, I., Lavie, V. and Schwartz, M. (1984) A new transorbital approach to the rabbit's optic nerve. *J. Neurosci. Methods* 12:259-262.
43. Hadani, M., Harel, A., Solomon, A., Belkin, M., Lavie, V. and Schwartz, M. (1984) Substances originating from optic nerve of neonatal rabbit induce regeneration-associated response in the injured optic nerve of adult rabbit. *Proc. Natl. Acad. Sci. USA* 81:7965-7969.
44. Schwartz, M., Belkin, M., Harel, A., Solomon, A., Lavie, V., Hadani, M., Rachailovich, I. and Stein-Izsak, C. (1985) Regenerating fish optic nerves and a regeneration-like response in injured optic nerves of adult rabbits. *Science* 228:600-603.
45. Stein-Izsak, C., Harel, A., Solomon, A., Belkin, M. and Schwartz, M. (1985) Alterations in mRNA translation products associated with regenerative response in the retina. *J. Neurochem.* 45:1754-1760.
46. Mizrachi, Y., Rubinstein, M., Kimhi, Y. and Schwartz, M. (1985) A neurotrophic factor derived from goldfish brain: Characterization and purification. *J. Neurochem.* 46:1675-1682.
47. Bawnik, Y., Harel, A., Stein-Izsak, C. and Schwartz, M. (1986) Environmental changes induced by growth associated triggering factors in injured optic nerve of adult rabbit. *Proc. Natl. Acad. Sci. USA* 84:2528-2531.
48. Rochkind, S., Nissan, M., Razon, N., Schwartz, M. and Bartal, A. (1986) Electrophysiological effect of He-Ne laser on normal and injured sciatic nerve in the rat. *Acta Neurochir.* 83:125-130.
49. Lavie, V., Harel, A., Doron, A., Solomon, A., Lobel, D., Belkin, M., Ben-Bassat, S., Sharma, S. and Schwartz, M. (1987) Morphological response of injured adult rabbit optic nerve to implants containing neonatal derived substances. *Brain Res.* 419:166-172.
50. Zak, N., Harel, A., Bawnik, Y., Ben-Bassat, S., Vogel, Z. and Schwartz, M. (1987) Laminin immunoreactive sites are indeed by growth-associated triggering factors in injured rabbit optic nerve. *Brain Res.* 408:263-266.

51. Schwartz, M., Doron, A., Ehrlich, M., Lavie, V., Ben-Bassat, S. and Belkin, M. (1987) Effects of low energy laser irradiation on posttraumatic degeneration of adult rabbit optic nerve. *Lasers Surg. Med.* 7:51-55.
52. Rochkind, S., Barnea, L., Razon, N., Bartal, A. and Schwartz, M. (1987) Stimulatory effect of He-Ne low dose laser on injured sciatic nerves of rats. *Neurosurgery* 20:843-847.
53. Stein-Izsak, C., Cohen, I.R. and Schwartz, M. (1987) Expression of the proto-oncogenes fos and myc in optic nerve regeneration. *Neurosci. Res. Commun.* 1:87-95.
54. Solomon, A., Belkin, M., Harel, A., Rosner, M., Ben-Bassat, S., Lavie, V., Ehrlich, M. and Schwartz, M. (1988) Optic nerve regeneration: New aspects. *Metab. Pediatr. Ophthalmol.* 11:31-32.
55. Fainaru, M., Schafer, Z., Gavish, D., Harel, A. and Schwartz, M. (1988) Interactions between human and carp (*Cyprinus carpio*) low density lipoproteins (LDL) and LDL receptors. *Comp. Biochem. Physiol.-B.* 91:331-338.
56. Assia, E., Rosner, M., Belkin, M., Solomon, A. and Schwartz, M. (1989) Temporal parameters and low energy laser irradiation for optimal delay of posttraumatic degeneration of rat optic nerve. *Brain Res.* 476:205-212.
57. Cohen, A. and Schwartz, M. (1989) Modulation of laminin levels in glial cells by regeneration-associated substances. *J. Neurosci. Res.* 22:269-273.
58. Harel, A., Fainaru, M., Shafer, Z., Hernandez, M. and Schwartz, M. (1989) Optic nerve regeneration in adult fish and apolipoprotein-A-I. *J. Neurochem.* 52:1218-1228.
59. Cohen, A., Sivron, T., Duvdevani, R. and Schwartz, M. (1990) Oligodendrocyte cytotoxic factor associated with fish optic nerve regeneration: Implications for mammalian CNS regeneration. *Brain Res.* 537:24-32.
60. Lavie, V., Murray, M., Solomon, A., Ben-Bassat, S., Belkin, M., Rumelt, S. and Schwartz, M. (1990) Growth of injured CNS axons within their degenerating optic nerve. *J. Comp. Neurol.* 298:293-314.
61. Harel, A., Fainaru, M., Rubinstein, M., Tal, N. and Schwartz, M. (1990) Fish apolipoprotein-A-I has heparin binding activity; implication for nerve regeneration. *J. Neurochem.* 55:1237-1243.
62. Duvdevani, R., Rosner, M., Belkin, M., Sautter, J., Sabel, B.A. and Schwartz, M. (1990) Graded crush of the rat optic nerve as a brain injury model: Combining electrophysiological, histological and behavioral outcome. *J. Restor. Neurol. Neurosci.* 2:31-38.
63. Blaugrund, E., Bartch, U., Martini, R., Schachner, M. and Schwartz, M. (1990) Immunological evidence that the neural adhesion molecule L1 is expressed in fish brain and optic nerve: Possible association with optic nerve regeneration. *Brain Res.* 530:239-244.
64. Sivron, T., Cohen, A., Duvdevani, R., Jeserich, G. and Schwartz, M. (1990) Glial response to axonal injury: *In vitro* manifestation and implication for regeneration. *Glia* 3:267-276.
65. Schwartz, M., Solomon, A., Lavie, V., Ben-Bassat, S., Belkin, M. and Cohen, A. (1991) Tumor necrosis factor facilitates regeneration of injured central nervous system axons. *Brain Res.* 545:334-338.
66. Sivron, T., Cohen, A., Hirschberg, D.L., Jeserich, G. and Schwartz, M. (1991) Soluble factor(s) produced in injured fish optic nerve regulates the postinjury number of oligodendrocytes: Possible role of macrophages. *Glia* 4:591-601.
67. Solomon, A., Lavie, V., Ben-Bassat, S., Belkin, M. and Schwartz, M. (1991) New surgical approach to overcome the inability of injured mammalian axons to grow within their environment. *J. Neurol. Transpl.* 2:243-248.

68. Blaugrund, E., Cohen, I.R., Shani, Y. and Schwartz, M. (1991) Glial fibrillary acidic protein in the fish optic nerve. *Glia* 4:393-399.
69. Cohen, I.R., Shani, Y., Blaugrund, E. and Schwartz, M. (1991) Isolation and sequence analysis of two intermediate filament cDNA clones from fish optic nerve. *Mol. Brain Res.* 11:181-185.
70. Sautter, J., Schwartz, M., Duvdevani, R. and Sabel, B.A. (1991) GM1 ganglioside treatment reduces visual deficits after graded crush of the rat optic nerve. *Brain Res.* 565:23-33.
71. Lotan, M. and Schwartz, M. (1992) Postinjury changes in platelet-derived growth factor-like activity in fish and rat optic nerves. *J. Neurochem.* 58:1637-1642.
72. Battisti, W.P., Shinar, Y., Schwartz, M., Levitt, P. and Murray, M. (1992) Temporal and spatial patterns of expression of laminin chondroitin sulfate proteoglycan and HNK-1 immunoreactivity during regeneration in the goldfish optic nerve. *J. Neurocytol.* 21:557-573.
73. Blaugrund, E., Sharma, S. and Schwartz, M. (1992) L1 immunoreactivity in the developing fish visual system. *Brain Res.* 574:244-250.
74. Lavie, V., Solomon, A., Ben-Bassat, S., Belkin, M. and Schwartz, M. (1992) Anterograde transport of horseradish peroxidase in injured rabbit optic nerve axons growing in their own environment. *Brain Res.* 575:1-5.
75. Eitan, S., Zisling, R., Cohen, A., Belkin, M., Hirschberg, D.L., Lotan, M. and Schwartz, M. (1992) Identification of an interleukin 2-like substance as a factor cytotoxic to oligodendrocytes and associated with central nervous system regeneration. *Proc. Natl. Acad. Sci. USA* 89:5442-5446.
76. Sivron, T., Jeserich, G., Nona, S. and Schwartz, M. (1992) Characteristics of glial cells in culture: Possible implication as to their lineage. *Glia* 6:52-66.
77. Blaugrund, E., Duvdevani, R., Lavie, V., Solomon, A. and Schwartz, M. (1992) Disappearance of astrocytes and invasion of macrophages following crush injury of adult rodent optic nerve: implication for regeneration. *Exp. Neurol.* 118:105-115.
78. Eitan, S. and Schwartz, M. (1993) A novel transglutaminase that converts interleukin-2 to a factor cytotoxic to oligodendrocytes. *Science* 261:106-108.
79. Yoles, E., Zalish, M., Lavie, V., Duvdevani, R., Ben-Bassat, S. and Schwartz, M. (1992) GM1 reduces early injury-induced metabolic deficits and subsequent degeneration in the rat optic nerve. *Invest. Ophthalmol. Vis. Sci.* 33:3586-3591.
80. Zalish, M., Lavie, V., Duvdevani, R., Yoles, E. and Schwartz, M. (1993) Gangliosides attenuate axonal loss after optic nerve injury. *Retina* 13:145-147.
81. Blaugrund, E., Lavie, V., Cohen, I.R., Schreyer, D.Y. and Schwartz, M. (1993) Axonal regeneration is associated with glial migration: comparison between the injured optic nerves of fish and rats. *J. Comp. Neurol.* 330:105-112.
82. Cohen, I.R. and Schwartz, M. (1993) cDNA clones from fish optic nerve. *J. Comp. Biochem. Physiol.* 104:439-447.
83. Cohen, I.R., Shani, Y. and Schwartz, M. (1993) Cloning and characteristics of fish glial fibrillary acidic protein: implication for optic nerve regeneration. *J. Comp. Neurol.* 334:431-443.
84. Sivron, T., Eitan, S., Schreyer, D.J. and Schwartz, M. (1993) Astrocytes play a major role in control of neuronal proliferation *in vitro*. *Brain Res.* 629:199-208
85. Cohen, I.R., Sivron, T., Lavie, V., Blaugrund, E. and Schwartz, M. (1994) Vimentin immunoreactive glial cells in fish optic nerve: Implication for regeneration. *Glia* 10:16-29.

86. Sivron, T., Cohen, I.R. and Schwartz, M. (1994) Intermediate filaments reminiscent of immature cells expressed by goldfish (*Carassius auratus*) astrocytes and oligodendrocytes *in vitro*. *Cell Tissue Res.* 275:327-337.
87. Sivron, T., Schwab, M.E. and Schwartz, M. (1994) Presence of growth inhibitors in fish optic nerve myelin: postinjury changes. *J. Comp. Neurol.* 343:237-246.
88. Lotan, M., Solomon, A., Ben-Bassat, S. and Schwartz, M. (1994) Cytokines modulate the inflammatory response and change permissiveness to neuronal adhesion in injured mammalian central nervous system. *Exp. Neurol.* 126:284-90.
89. Hirschberg, D.L., Yoles, E., Belkin, M. and Schwartz, M. (1994) Inflammation after axonal injury has conflicting consequences for recovery of function: rescue of spared axons is impaired but regeneration is supported. *J. Neuroimmunol.* 50:9-16.
90. Eizenberg, O., Kaplitt, M., Hirschberg, D.L., Pfaff, D., Eitan, S. and Schwartz, M. (1994) Linear dimeric interleukin-2 obtained by use of a defective herpes simplex viral vector: conformation-activity relationship. *Mol. Brain Res.* 26:156-162.
91. Eitan, S., Solomon, A., Lavie, V., Yoles, E., Hirschberg, D.L., Belkin, M. and Schwartz, M. (1994) Recovery of visual response of injured adult rat optic nerves treated with transglutaminase. *Science* 264:1764-1768.
92. Pinkas-Kromarski, R., Eilan, R., Lazarov-Spiegler, O., Lari, S., Liu, N., Chang, D., Wen, D., Schwartz, M. and Yarden, J. (1994) Brain neurons and glial cells express NDF/heregulin: a survival factor for astrocytes *Proc. Natl. Acad. Sci. USA* 91:9387-9391.
93. Sivron, T. and Schwartz, M. (1994) Nonpermissive nature of fish optic nerves to axonal growth is due to presence of myelin-associated growth inhibitors. *Exp. Neurol.* 130:411-413.
94. Eizenberg, O., Faber-Elman, A., Lotan, M. and Schwartz, M. (1995) Interleukin-2 transcripts in human and rodent brains: possible expression by astrocytes. *J. Neurochem.* 64:1928-1936.
95. Eizenberg, O., Faber-Elman, A., Gottlieb, E., Oren, M., Rotter, V. and Schwartz, M. (1995) Direct involvement of p53 in programmed cell death of oligodendrocytes. *EMBO J.* 14:1136-1144.
96. Faber-Elman, A., Miskin, R. and Schwartz, M. (1995) Components of the plasminogen activator system in astrocytes are modulated by tumor necrosis factor- α and interleukin-1 through similar signal transduction pathways. *J. Neurochem.* 65:1524-1535.
97. Faber-Elman, A., Schwartz, I., Shaltiel, S. and Schwartz, M. (1995) Vitronectin overrides a negative effect of TNF- α on astrocyte migration. *FASEB J.* 9:1605-1613.
98. Faber-Elman, A., Solomon, A., Abraham, J.A., Marikovsky, M. and Schwartz, M. (1996) Involvement of wound-associated factors in rat brain astrocyte migratory response to axonal injury: *in vitro* simulation. *J. Clin. Invest.* 97:162-171.
99. Hirschberg, D.L., and Schwartz, M. (1995) Macrophage recruitment to the acutely injured central nervous system is inhibited by a resident factor: A basis for an immune-brain barrier. *J. Neuroimmunol.* 61:89-96.
100. Lazarov-Spiegler, O., Solomon, A.S., Hirschberg, D.L., Lavie, V., and Schwartz, M. (1996) Transplantation of activated macrophages overcomes central nervous system regrowth failure. *FASEB J.* 10:1296-1302.
101. Eizenberg, O., Faber-Elman, A., Gottlieb, E., Oren, M., Rotter, V. and Schwartz, M. (1996) p53 plays a regulatory role in differentiation and apoptosis of central nervous system-associated cells. *Mol. Cell. Biol.* 16:5178-5185.

102. Yoles, E., Belkin, M. and Schwartz, M. (1996) HU-211, a nonpsychotropic cannabinoid, produces short- and long-term neuroprotection after optic nerve axotomy. *J. Neurotrauma* 13:49-57.
103. Solomon, A.S., Lavie, V., Hauben, U., Monsonogo, A., Yoles, E. and Schwartz, M. (1996) Complete transection of rat optic nerve while sparing the meninges and the vasculature: an experimental model for optic nerve neuropathy and trauma. *J. Neurosci. Methods*. 70:21-25.
104. Monsonogo, A., Shani, Y., Friedmann, I., Eizenberg, O., Paas, Y. and Schwartz, M. (1997) Expression of GTP-dependent and GTP-independent tissue-type TGase in cytokine-treated rat brain astrocytes. *J. Biol. Chem.* 272:3724-3732.
105. Ben Zeev-Brann, A., Lazarov-Spiegler, O., Brenner, T. and Schwartz, M. (1998) Macrophage/microglia activity as a function of the interacting nerve: Comparison between PNS and CNS. *Glia* 22:181-190.
106. Yoles, E., Muler, S. and Schwartz, M. (1997) N-methyl-D-aspartate-receptor antagonist protects neurons from secondary degeneration after partial optic nerve crush. *J. Neurotrauma* 14:665-675.
107. Lazarov-Spiegler, O., Solomon, A.S. and Schwartz, M. (1998) Central nervous system inhibits phagocytic activity of macrophages: Implications for poor removal of myelin and failure of regeneration. *Glia* 24:329-337.
108. Yoles, E. and Schwartz, M. (1998) Elevation of intraocular glutamate in rats with partial lesion of the optic nerve. *Arch. Ophthalmol.* 116:906-910.
109. Monsonogo, A., Mizrahi, T., Eitan, S., Moalem, G., Bardos, H., Adani, R. and Schwartz, M. (1998) Factor XIIIa as a nerve-associated transglutaminase. *FASEB J.* 16:1163-1171.
110. Yoles, E. and Schwartz, M. (1998) Evidence for secondary degeneration of spared neurons following partial white matter lesion: implications for optic nerve neuropathies. *Exp. Neurol.* 153:1-7 (cover picture).
111. Hirschberg, D.L., He, J., Moalem, G., Mor, P., Cohen, I.R. and Schwartz, M. (1998) T cells homing to injured central nervous system. *J. Neuroimmunol.* 89:88-96.
112. Lazarov-Spiegler, O., Solomon, A.S. and Schwartz, M. (1998) The inflammatory reaction is an essential process for adult mammalian CNS regrowth. *Vision Res.* 39:169-175.
113. Rapalino, O., Lazarov-Spiegler, O., Agranov, E., Velan, G., Yoles, E., Solomon, A., Gepstein, R., Katz, A., Belkin, M., Hadani, M. and Schwartz, M. (1998) Implantation of stimulated macrophages leads to partial recovery of paraplegic rats. *Nat. Med.* 4:814-821.
114. Monsonogo, A., Friedman, I., Eizenstein, M. and Schwartz, M. (1998) A GTP-dependent structural/functional switch in a mutually exclusive dual-active enzyme. *J. Mol. Biol.* 282:713-720.
115. Moalem, G., Leibowitz-Amit, R., Yoles, E., Cohen, I.R. and Schwartz, M. (1999) Autoimmune T cells limit secondary degeneration following central nervous system trauma. *Nat. Med.* 5:49-65 (main topic on cover page and cover picture)
'News and Views' Novak K. Autoimmune T cells - not always bad guys. *Nature Med.* 5:28.
116. Yoles, E., Wheeler, L.A. and Schwartz, M. (1999) Alpa-2-adrenoreceptor agonists are neuroprotective in an experimental model of optic nerve degeneration in the rat. *Invest. Ophthalmol. Vis. Sci.* 40:65-73. (cover picture).
117. Friedmann, I., Faber-Elman, A., Yoles, E. and Schwartz, M. (1999) Injury-induced gelatinase and thrombin-like activities in regenerating nervous systems. *FASEB J.* 13:533-543.
118. Moalem, G., Monsonogo, A., Shani, Y., Cohen, I.R. and Schwartz, M. (1999) Differential T cell response in central and peripheral nerve injury; connection to immune privilege. *FASEB J.* 13:1207-1217.

119. Hauben, E., Nevo, U., Yoles, E., Moalem, G., Agranov, E., Mor, F., Akselrod, S., Neeman, M., Cohen, I.R. and Schwartz, M. (2000) Autoimmune T cells are neuroprotective in Spinal cord injury. *Lancet*. 355:286-287.
120. Moalem, G., Leibowitz-Amit, R., Yoles, E., Muller-Gilg, S., Mor, F., Cohen, I.R. and Schwartz, M. (2000) Autoimmune T cells retard the loss of function in injured rat optic nerves. *J. Neuroimmunol.* 106:189-197.
121. Hauben, E., Butovsky, O., Nevo, U., Yoles, E., Moalem, G., Agranov, E., Leibowitz-Amit, R., Mor, F., Pevsner, E., Akselrod, S., Neeman, M., Cohen, I.R. and Schwartz, M. (2000) Benign Autoimmunity: Neuroprotection by Autoimmune T cells in a Rat Model of Spinal Cord Contusion. *J. Neurosci.* 20:6421-6430.
122. Kipnis, J., Yoles, E., Cohen, A., Sela, M., Cohen, I.R. and Schwartz, M. (2000) Immunization with copolymer-1 confers neuroprotection on the damaged optic nerve: possible therapy for optic neuropathies. *Proc. Natl. Acad. Sci. (USA)* 97:7446-7451.
123. Moalem, G., Gdalyahu, A., Shani, Y., Otten, U., Lazarovici, P., Cohen, I.R. and Schwartz, M. (2000) Production of neurotrophins by activated T cells: implications for neuroprotective autoimmunity. *J. Autoimmunity* 15: 331-345.
124. Levkovitch-Verbin, H., Harris-Cerruti, C., Groner, Y., Wheeler, L.A., Schwartz, M. and Yoles, E. (2000) Retinal ganglion cell death in mice after optic nerve crush injury: Effects of superoxide dismutase overexpression and protection via the alpha-2 adrenoreceptor pathway. *Invest. Ophthalmol. Vis. Sci.* 41:4169-4174.
125. Yoles, E., Friedmann, I., Barouch, R., Shani, Y. and Schwartz, M. (2001) Self-Protective mechanism awakened by glutamate in retinal ganglion cells. *J. Neurotrauma* 18:339-349.
126. Nevo, U., Hauben, U., Yoles, E., Agranov, E., Cohen, I.R., Akselrod, S., Schwartz, M. and Neeman, M. (2001) Diffusion anisotropy MRI for quantitative assessment of recovery in injured rat spinal cord. *Magnetic Resonance in Medicine* 45: 1-9.
127. Schori, H., Yoles, E., Kipnis, J., WoldeMussie, E., Ruiz, G., Wheeler, L.A. and Schwartz, M. (2001) Vaccination for protection of neurons against glutamate cytotoxicity and ocular hypertension: implications for glaucoma. *Proc. Natl. Acad. Sci. (USA)* 13:3398-403.
128. Kipnis, J., Yoles, E. and Schwartz, M. (2001) Genetic control of immune response to trauma: vaccination for acute and chronic CNS degenerative disorders. *J. Neurosci.* 21:4564-4571.
129. Yoles, E., Hauben, E., Palgi, O., Eugenia, A., Kuchroo, V., Cohen, I.R., Weiner, H. and Schwartz, M. (2001) Beneficial autoimmunity is a physiological response to central nervous system trauma. *J. Neurosci.* 21:3740-3748.
130. Schori, H., Yoles, E., and Schwartz, M. (2001) T-cell-based immunity counteracts the potential toxicity of glutamate in the central nervous system. *J. Neuroimmunol.* 119:199-204.
131. Fisher, J., Yoles, E., Levkovitch-Verbin, H., Kaye, J.F., Ben-Nun, A. and Schwartz, M. (2001) Vaccination for neuroprotection in the mouse optic nerve: implication for optic neuropathies. *J. Neurosci.* 21: 136-142.
132. Friedmann, I., Yoles, E. and Schwartz, M. (2001) The thrombin inhibitor NAPAP is neuroprotective in the injured rat optic nerve. *J. Neurochem.* 76: 641-649.
133. Butovsky, O., Hauben, E. and Schwartz, M. (2001) Morphological aspects of spinal cord autoimmune neuroprotection-colocalization of T cells with B7-2 (CD86) and prevention of cyst formation. *FASEB J.* 15:1065-1067.

134. Fisher, J., Mizrahi, T., Yoles, E., Levkovitch-Verbin, H., Haggiag, S., Revel, M. and Schwartz, M. (2001) Increased post-traumatic survival of neurons in interleukin-6 deficient mice. *J. Neuroimmunol.* 119: 1-9.
135. Hauben, E., Agranov, E., Gothilf, A., Nevo, U., Cohen, A., Smirnov, I., Schwartz, M. (2001) Post-traumatic immunization for spinal cord recovery: benefit without risk of pathogenicity. *J Clin Invest.* 108: 591-599
136. Hauben, E., Ibarra, I., Mizrahi, T., Barouch, R., Agranov, E., and Schwartz, M. (2001) Vaccination with a Nogo-A-derived peptide after incomplete spinal cord injury promotes recovery via a T-cell-mediated neuroprotective response: Comparison with other myelin antigens *Proc. Natl. Acad. Sci. (USA)* 98: 15173-15178.
137. Bakalash, S., Yoles, E. and Schwartz, M. (2002) Resistance of retinal ganglion cells to an increase in intraocular pressure is immune-dependent. *Invest. Ophthalmol. Vis. Sci.*, 43: 2648-2653.
138. Barouch, R. and Schwartz, M. (2002) Autoreactive T cells induce neurotrophin production by immune and neural cells in injured rat optic nerve: Implications for protective autoimmunity. *FASEB J.* 16:1304-1306.
139. Mizrahi, T. and Schwartz, M. (2002) The tissue-specific self-pathogen is the protective self-antigen: The case of uveitis. *J. Immunol.* 169:5971-5977.
140. Kipnis, J., Mizrahi, T., Yoles, E., Ben-Nun, A. and Schwartz, M. (2002) Myelin specific Th1 cells are necessary for post-traumatic protective autoimmunity. *J. Neuroimmunol.* 130:78-85.
141. Schori, H., Yoles, E., Wheeler, L.A. and Schwartz, M. (2002) Immune related mechanisms participating in resistance and susceptibility to glutamate toxicity. *Eur. J. Neurosci.* 16:557-564.
142. Kipnis, J., Hauben, E., Mizrahi, T., Shaked, I., Shevach, E. and Schwartz, M. (2002) Neuroprotective autoimmunity: Naturally occurring CD4+CD25+ regulatory T cells suppress the ability to withstand injury to the central nervous system. *Proc. Natl. Acad. Sci. (USA)* 99:15620-15625.
143. Schwartz, M. and Hauben, E. (2002) Differing views on spinal cord repair. *Science* 296:1400.
144. Schori, H., Lantner, F., Shachar, I. and Schwartz, M. (2002) Severe immunodeficiency has opposite effects on neuronal survival in glutamate-susceptible and -resistant mice: Adverse effect of B cells. *J. Immunol.*, 169:2861-2865.
145. Hauben, E., Mizrahi, T., Agranov, E., and Schwartz, M. (2002) Sexual dimorphism in the spontaneous recovery from spinal cord injury: a gender gap in beneficial autoimmunity?. *Eur. J. Neurosci.* 16:1731-1740.
146. Shaked, I., Kipnis, J., Porat, Z. and Schwartz, M. (2002) Local cellular aspects of protective autoimmunity in the CNS following axotomy. Submitted.

B. Invited Reviews

141. Schwartz, M. (1986) Molecular and cellular aspects of nerve regeneration. *CRC Biochem.* 22:89-110.
142. Belkin, M., Zaturinsky, B. and Schwartz, M. (1988) A critical review of low energy laser bioeffects. I. Basic aspects. *Laser Light Ophthalmol.* 2:63-71.
143. Belkin, M. and Schwartz, M. (1989) New biological phenomena associated with laser irradiation. *Health Phys.* 56:687-690.
144. Schwartz, M., Cohen, A., Stein-Izsak, C. and Belkin, M. (1989) Dichotomy of the glial cell response to axonal injury and regeneration. *FASEB J.* 3:2371-2378.

145. Schwartz, M. (1993) Recent scientific endeavours to comprehend the mysterious inability of humans to repair injuries to their brain and spinal cord. *Endeavour*.17:38-40.
146. Schwartz, M. and Belkin, M. (1994) Evidence for the existence of low-energy laser: Bioeffects on the nervous system. *Neurosurg. Rev.* 17:7-17.
147. Sivron, T. and Schwartz, M. (1994) The enigma of myelin-associated growth inhibitors in spontaneously regenerating nervous system. *Trends Neurosci.* 17:277-281.
148. Lotan, M. and Schwartz, M. (1994) Cross talk between the immune system and the nervous system in response to injury : Implications for regeneration. *FASEB J.* 8:1026-1033.
149. Belkin, M. and Schwartz, M. (1994) Ophthalmic effects of low-energy laser irradiation. *Surv. Ophthalmol.* 39:113-121.
150. Schwartz, M., Belkin, M. Solomon, A., Shosh, E., Lavie, V., Hirschberg, D.L., Yoles, E., Faber-Elman, A., Beserman, P. and Lazarov-Spiegler, O. (1995) Optic nerve disease and injury: Prospects for induction of regeneration. *Prog. Retinal Eye Res.* 15:569-581.
151. Sivron, T. and Schwartz, M. (1995) Glial cell types, lineage, and response to injury in rat and fish: implication for regeneration. *Glia* 13:157-165.
152. Schwartz, M., Hirschberg, L. D. and Beserman, P. (1995) Central nervous system regeneration and the immune system. *Mol. Med. Today* 1:60-61.
153. Schwartz, M. Yoles, E., Belkin, M. and Solomon, A. (1996) Potential treatment modalities for glaucomatous neuropathy: Neuroprotection and neuroregeneration. *J. Glaucoma* 5:427-432.
154. Schwartz, M. and Lazarov-Spiegler, O. (1998) The role of the immune system in central nervous system recovery: An evolutionary perspective. *Curr. Top. Neurochem.* 1:123-132.
155. Lazarov-Spiegler, O. Rapalino, O., Agranov, E. and Schwartz, M. (1998) Restricted inflammatory reaction in the CNS: A key impediment to axonal regeneration *Mol. Med. Today* 4:337-342 (main topic on cover page and cover picture)
156. Yoles, E. and Schwartz, M. (1998) Potential neuroprotective therapy for glaucomatous optic neuropathy. *Surv. Ophthalmol* 42:367-372.
157. Schwartz, M., Lazarov-Spiegler, O., Rapalino, O., Agranov, E. and Velan, G. (1999) Potential repair of spinal cord injuries using suitably stimulated autologous macrophages. *J. Neurosurg.* 44:1041-1046.
158. Schwartz, M., Moalem, G., Lazarov-Spiegler, O., and Cohen, I.R. (1999) Innate and acquired immune responses are beneficial for CNS repair and rescue: Compatibility with immune privilege. *Trends Neurosci.* 22:265-269.
159. Schwartz, M. Yoles, E. and Levin, L. (1999) Axogenic and somagenic degenerative diseases: Definitions and therapeutic implications. *Mol. Med. Today* 5:470-473.
160. Schwartz, M. and Yoles, E. (1999) "New developments" Self-destructive and self-protective processes in the damaged optic nerve: Implications for glaucoma. *Invest. Ophthalmol. Vis. Sci.* 41:349-351.
161. Schwartz, M. and Cohen, I.R. (2000) Autoimmunity can benefit self-maintenance. *Immunol. Today* 21:253-256. (main topic on cover page)
162. Schwartz, M. and Yoles, E. (2000) Cellular and molecular basis of neuroprotection: Implications for optic neuropathies. *Curr. Opin. Ophthalmol.* 11:107-111.

163. Cohen I.R. and Schwartz, M. (2000) Autoimmune maintenance and repair of the central nervous system. *J. Neuroimmunol.* 100:111-114.
164. Schwartz, M. (2000) Beneficial autoimmune T cells and posttraumatic neuroprotection. *Ann. N.Y. Acad. Sci.* 917:341-347.
165. Schwartz, M. (2000) Autoimmune involvement in CNS trauma is beneficial if well controlled. *Progress in Brain Res.* 128: 259-263.
166. Schwartz, M. (2001) Immunological approaches to the treatment of spinal cord injury. *BioDrugs* 15:585-593.
167. Schwartz, M. (2001) T cell mediated neuroprotection is a physiological response to central nervous system insults. *J. Mol. Med.* 78: 594-597.
168. Schwartz, M. and Kipnis, J. (2001) Genetic control of immune response to trauma: vaccination for acute and chronic CNS degenerative disorders. *Trends in Mol. Med.* 7:252-258. (main topic on cover page and cover picture).
169. Schwartz, M. (2001) Post-traumatic CNS maintenance and repair by autoimmune T cells. *Prog. Neurobiol.* 65:489-496.
170. Schwartz, M. (2001) Neuroprotection as a treatment for glaucoma: Pharmacological and immunological approaches. *Eur. J. Ophthalmol.* 11 Suppl. 2:S7-11.
171. Schwartz, M. (2001) Physiological approaches to neuroprotection. Boosting of protective autoimmunity. *Surv. Ophthalmol.* 45 Suppl 3:S256-60; discussion S273-276.
172. Schwartz, M. and Moalem, G. (2001) Beneficial immune activity after CNS injury: prospects for vaccination. *J. Neuroimmunol.* 113:185-192.
173. Schwartz, M. (2001) Harnessing the immune system for neuroprotection: therapeutic vaccines for acute and chronic neurodegenerative disorders. *Cell. Mol. Neurobiol.* 21:617-627.
174. Kipnis, J. and Schwartz, M. (2002) Dual action of glatiramer acetate (Cop-1) in the treatment of CNS autoimmune and neurodegenerative disorders. *Trends Mol. Med.* 8:319-323.
175. Schwartz, M. and Kipnis, J. (2002) Multiple sclerosis as a by-product of the failure to sustain protective autoimmunity: A paradigm shift. *The Neuroscientist*, 8:405-13.
176. Schwartz, M. and Hauben, E. (2002) T cell-based therapeutic vaccination for spinal cord injury. *Prog. Brain Res.* 137:401-406.
177. Hauben, E. and Schwartz, M. (2002) Therapeutic vaccination for spinal cord injury: Helping the body to cure itself. *Trends Pharmacol.* in press.
178. Schwartz, M. and Kipnis, J. (2002) Prospects for therapeutic vaccination with glatiramer acetate for neurodegenerative diseases such as Alzheimer's disease. *Drug Dev. Res.* 56:143-149.
179. Schwartz, M. and Kipnis, J. (2002) Autoimmunity on Alert: Naturally Occurring Regulatory CD4+CD25+ T cells as Part of the Evolutionary Compromise Between a "Need" and a "Risk". *Trends Immunol.* 23:530-534.
180. Schwartz, M. The immune system protects against glutamate, the enemy from within: Scientific and clinical implications. *Trends Neurosci.* 2002.
181. Schwartz, M. Neurodegeneration and neuroprotection in glaucoma: Development of a therapeutic neuroprotective vaccine. *Invest. Ophthalmol. Vis. Sci.*, in press.

C. Selected Recent Book Chapters

173. **Schwartz, M.** Beneficial autoimmune T cells and posttraumatic neuroprotection. In: *Neuroimmunomodulation: Perspectives at the New Millenium*. (A. Conti, G.J.M. Maestroni, S.M. McCann, E.M. Sternberg, J.M. Lipton, Eds.), Elsevier Science, B.V., pp. 341-347, 2000.
174. **Schwartz, M.** Salutory effect of autoimmune T cells after central nervous system injury. In: *Inflammation and Stroke*. (G.Z. Feuerstein, Ed.), Martin Dunitz Ltd., pp. 37-48, 2001.
175. **Schwartz, M.** Protective autoimmunity: is vaccination for neurodegenerative disorders feasible? In: *Brain Disease: Therapeutic Strategies and Repair*. (O. Abramsky, D.A.S. Compston, A. Miller, G. Said, Eds.), Martin Dunitz Ltd., pp. 225-230, 2002.
176. **Schwartz, M.** Development of therapeutic vaccines for glaucoma. In: *Innovations in the Glaucomas: Etiology, Diagnosis and Management*. (M. Luntz, Ed.), In press???

Vaccination with a Nogo-A-derived peptide after incomplete spinal-cord injury promotes recovery via a T-cell-mediated neuroprotective response: Comparison with other myelin antigens

Ehud Hauben, Antonio Ibarra, Tal Mizrahi, Rina Barouch, Eugenia Agranov, and Michal Schwartz*

Department of Neurobiology, Weizmann Institute of Science, Rehovot 76100, Israel

Communicated by Michael Sela, Weizmann Institute of Science, Rehovot, Israel, November 1, 2001 (received for review September 24, 2001)

The myelin-associated protein Nogo-A has received more research attention than any other inhibitor of axonal regeneration in the injured central nervous system (CNS). Circumvention of its inhibitory effect, by using antibodies specific to Nogo-A, has been shown to promote axonal regrowth. Studies in our laboratory have demonstrated that active or passive immunization of CNS-injured rats or mice with myelin-associated peptides induces a T-cell-mediated protective autoimmune response, which promotes recovery by reducing posttraumatic degeneration. Here, we show that neuronal degeneration after incomplete spinal-cord contusion in rats was substantially reduced, and hence recovery was significantly promoted, by posttraumatic immunization with p472, a peptide derived from Nogo-A. The observed effect seemed to be mediated by T cells and could be reproduced by passive transfer of a T cell line directed against the Nogo-A peptide. Thus, it seems that after incomplete spinal-cord injury, immunization with a variety of myelin-associated peptides, including those derived from Nogo-A, can be used to evoke a T cell-mediated response that promotes recovery. The choice of peptide(s) for clinical treatment of spinal-cord injuries should be based on safety considerations; in particular, the likelihood that the chosen peptide will not cause an autoimmune disease or interfere with essential functions of this peptide or other proteins. From a therapeutic point of view, the fact that the active cellular agents are T cells rather than antibodies is an advantage, as T cell production commences within the time window required for a protective effect after spinal-cord injury, whereas antibody production takes longer.

Substantial progress has been made in understanding why the injured central nervous system (CNS) fails to regenerate and why the damage caused by the primary insult is propagated rapidly and irreversibly beyond the initial lesion. In the search for answers to these questions, considerable attention has been directed to myelin-associated inhibitors (1). One such inhibitor is Nogo-A (2–6), which was recently cloned and characterized (7). Monoclonal antibodies to Nogo-A were reported to facilitate axonal regrowth and some functional recovery when injected into the cerebrospinal fluid of rats after partial transection of their spinal cords (8, 9).

Studies of animal models of partial and complete CNS lesions in our laboratory have shown that after CNS injury, the white blood cells of the immune system (macrophages and T lymphocytes) can facilitate processes of protection, repair, and regeneration (10–13). Axonal injury to the spinal cord evidently activates an anti-self (autoimmune) response mediated by T cells directed against myelin-associated antigens. This response was found to be beneficial for the injured nerve, as it can reduce the posttraumatic degeneration, an otherwise inevitable consequence of the injury (14). The ability to exhibit a protective autoimmune T cell response is genetically controlled and is inversely related to the inherent resistance of the individual or strain to the development of an autoimmune disease, such as

experimental autoimmune encephalomyelitis (EAE), when challenged with myelin-associated antigens (15). Moreover, the neuroprotective T cell response is amenable to boosting by passive or active immunization. Passive transfer of T cells reactive to myelin basic protein (MBP) significantly improves recovery from spinal-cord contusion in rats (10, 16).

In seeking a way to convert the experimental immunization into an effective posttraumatic therapy, we have been testing peptides that are “safe” (i.e., do not induce autoimmune disease) and are derived from or crossreact with self-proteins (17–19). We found that vaccination with MBP or a spinal-cord homogenate containing a variety of myelin proteins promotes morphological and functional recovery of the injured spinal cords of both EAE-resistant and EAE-susceptible rats (17). This finding raised another question: would vaccination with myelin antigens that inhibit axonal outgrowth be similarly (or more) effective, or is the effect unique to a specific type of myelin protein?

In this study, we examined whether posttraumatic immunization with a peptide derived from the myelin-associated growth-inhibitory protein Nogo-A (p472) can promote recovery from spinal-cord injury. If so, we were interested in finding out whether such peptides can reduce the spread of damage without risk of inducing an autoimmune disease, and whether the effect is mediated by antibodies or by T cells.

Materials and Methods

Animals. Inbred adult Sprague–Dawley (SPD) and Lewis rats (10–12 weeks old, 200–250 g) were supplied by the Animal Breeding Center of The Weizmann Institute of Science. The rats were matched for age and weight in each experiment and housed in a light- and temperature-controlled room.

Antigens. MBP and ovalbumin (OVA) were purchased from Sigma. Altered (nonencephalitogenic) MBP peptide (Ala-91) was derived from an encephalitogenic peptide, amino acids 87–99 of MBP, by replacing the lysine residue 91 with alanine (VHFFANIVTPRTP) (20). Both Ala-91 and the Nogo-A-derived peptide p472 (SYDSIKLEPENPPPYEEA) (7) were synthesized at the Weizmann Institute of Science (Rehovot, Israel). Antigens were emulsified in equal volumes of complete Freund's adjuvant (CFA; Difco) supplemented with *Mycobacterium tuberculosis* (1 mg/ml; Difco).

Spinal-Cord Contusion or Transection. Rats were anesthetized by i.p. injection of Rompun (xylazine, 10 mg/kg; Vitamed, Benyamina,

Abbreviations: CNS, central nervous system; EAE, experimental autoimmune encephalomyelitis; MBP, myelin basic protein; SPD, Sprague–Dawley; OVA, ovalbumin; CFA, complete Freund's adjuvant; RGC, retinal ganglion cells.

*To whom reprint requests should be addressed. E-mail: michal.schwartz@weizmann.ac.il. The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. §1734 solely to indicate this fact.

Israel) and Vetalar (ketamine, 50 mg/kg; Fort Dodge Laboratories, Overland Park, KS), and their spinal cords were exposed by laminectomy at the level of T9. One hour after induction of anesthesia, a 10-g rod was dropped onto the laminectomized cord from a height of 25 mm or 50 mm with the New York University (N.Y.U.) Impactor, a device shown to inflict a well calibrated contusive injury of the spinal cord (21). The spinal cords of another group of rats were transected completely, as described (13).

Active Immunization. Rats were immunized s.c. in the base of the tail on a random basis with 150 μ g of p472 or Ala-91 or were injected with PBS, each emulsified in an equal volume of CFA containing 1 mg/ml bacteria. Seven days later, each rat was injected s.c. with a booster of 100 μ g of the same antigen emulsified in incomplete Freund's adjuvant (Difco). The first immunization was given not later than 1 h after contusion. Control rats were sham-operated (laminectomized but not contused), immunized, and examined daily for symptoms of EAE, which were scored on a scale of 1 to 5 (22).

SPD T Cell Line Specific to p472. T cell line was generated from draining lymph-node cells obtained from immunized rats as described (23). Cells were grown in propagation medium for 4–10 days before being restimulated with their antigen (10 μ g/ml) in the presence of irradiated (2,000 rad) thymus cells (1×10^7 cells per ml) in proliferation medium. The T cell line was expanded by repeated stimulation and propagation.

Animal Care. In contused rats, bladder expression was assisted by massage at least twice a day (and three times a day during the first 48 h after injury) until the end of the second week, by which time SPD rats had recovered automatic voidance. Lewis rats required this treatment throughout the experiment. All rats were carefully monitored for evidence of urinary tract infection or other signs of systemic disease. During the first week after contusion and in any case of hematuria thereafter, they received a course of sulfamethoxazole (400 mg/ml) and trimethoprim (8 mg/ml) (Resprim; Teva Pharmaceutical Industries, Petah Tikva, Israel), administered orally by syringe (0.3 ml of solution per day). Daily inspections included examination of the laminectomy site for evidence of infection and assessment of the hind limbs for signs of autophagia or pressure.

Proliferation Assay. Female SPD rats were immunized with p472. Ten days later, lymph nodes were excised, dissociated, and the washed lymphocytes (2×10^6 cells per ml) were cultured in 0.2 ml of proliferation medium (10). The cells were activated for 72 h at 37°C, 90% relative humidity, and 7% CO₂ in the presence of irradiated thymocytes (2,000 rad, 2×10^6 cells per ml), together with p472 (10 μ g/ml), Ala-91 in CFA (10 μ g/ml), the nonself antigen OVA (10 μ g/ml), Con A (1.25 μ g/ml), or no antigen. The proliferative response was determined by measuring the incorporation of [³H]thymidine (1 μ Ci per well; 1 Ci = 37 GBq), which was added for the last 16 h of a 72-h culture.

ELISA for Antibody Detection. For this assay, 96-well flat-bottomed microtiter plates treated with glutaraldehyde (0.2%) were coated with 100 μ l of p472 or Ala-91 (10 μ g/ml) in PBS, by overnight incubation at 4°C. The plates then were blocked with PBS containing 1% BSA (Sigma) for 2 h at 37°C and washed with PBS containing Tween 20 (0.5%). Duplicate samples of the sera to be tested were added to the plates at different dilutions in PBS containing 1% BSA (1:500, 1:1000, 1:5,000, or 1:10,000). The plates were incubated for 2 h at 37°C, then washed five times in PBS containing Tween 20 (0.5%). Peroxidase-conjugated AffiniPure goat anti-mouse IgG (Jackson ImmunoResearch) or alkaline phosphatase goat anti-mouse IgM (Jackson Immuno-

Research) diluted 1:2,500 in PBS and 1% BSA were added, and the plates were incubated for 2 h at 37°C. They were then washed five times in PBS containing Tween 20 (0.5%) and alkaline phosphatase substrate solution (100 μ l per well) was added. The reaction was stopped by the addition of 1 M phosphoric acid (100 μ l per well). The plates were read with an ELISA plate reader (Anthos Labec Instruments, Salzburg, Austria) OD at 405 nm (in wells with anti-IgM antibody) or OD at 450 nm (in wells with anti-IgG antibody). Background OD was subtracted from the test OD values.

Assessment of Recovery from Spinal-Cord Contusion. Behavioral recovery was scored in an open field with the Basso, Beattie, and Bresnahan locomotor rating scale (BBB), where a score of 0 registers complete paralysis and a score of 21 registers complete mobility (24). Blind scoring ensured that observers were not aware of the treatment received by each rat, as described (17). Before each evaluation, the rats were examined carefully for perineal infection, wounds in the hind limbs, and tail and foot autophagia.

Retrograde Labeling of Rubrospinal Neurons. Four months after spinal-cord contusion, rats were reanesthetized, and the dye rhodamine dextran amine (Fluoro-ruby; Molecular Probes) was applied below the site of contusion at T12. After 5 days, the rats again were anesthetized, and their brains were excised, processed, and cryosectioned. Sections taken through the red nucleus were inspected and analyzed qualitatively and quantitatively by fluorescence and confocal microscopy.

Partial Crush Injury of the Rat Optic Nerve. The optic nerve was subjected to crush injury, as described (14).

Measurement of Secondary Degeneration of the Rat Optic Nerve by Retrograde Labeling of Retinal Ganglion Cells (RGCs). Secondary degeneration of the optic nerve axons and their attached RGCs was measured after postinjury application of the fluorescent lipophilic dye 4-[4-(didecylamino)styryl]-N-methylpyridinium iodide (4-Di-10-Asp; Molecular Probes) distally to the lesion site 2 weeks after crush injury (25).

Results

Posttraumatic Vaccination with a Nogo-A-Derived Peptide Reduces Degeneration After Incomplete Spinal-Cord Partial Injury. We synthesized an 18-aa peptide (SYDSIKLEPENPPPYEEA) derived from Nogo-A (p472) and used it to vaccinate rats immediately after partial injury (contusion) of the spinal cord. The choice of peptide was based on previous observations that antibodies directed against p472 were as effective as the original IN-1 antibodies in blocking the myelin-inhibitory effect on neuronal growth, suggesting that this peptide might be the physiologically significant epitope within the Nogo-A protein (7, 26, 27). Rats were injected with p472 or PBS emulsified in CFA. Fig. 1 shows the recovery of spinally contused female and male SPD rats after immunization with p472. Female rats immunized with p472 after injury recovered significantly better than females that were untreated or injected with PBS in CFA. The effect was discernible less than 2 weeks after immunization and was stronger after 4 weeks (Fig. 1). The highest behavioral score (mean \pm SEM) obtained in the p472-vaccinated group ($n = 5$) was 8.0 ± 0.8 , compared with 3.4 ± 0.9 in the untreated group ($n = 5$). Control rats injected with PBS in CFA scored 5.5 ± 0.5 , which is higher than the untreated rats but still significantly lower than the p472-immunized rats. The above findings confirm that the endogenous immune response to a CNS insult can be boosted with myelin antigens and that the boosting has a beneficial effect (14). In all subsequent experiments, rats immunized with PBS in CFA were included as controls to verify that the effect induced




Fig. 1. Active posttraumatic vaccination with the Nogo-derived peptide p472 reduces paralysis after incomplete spinal-cord injury in SPD rats. Female SPD rats were subjected to spinal contusion at T8 inflicted by the N.Y.U. Impactor with a 10-g weight dropped from a height of 50 mm. Immediately after contusion, rats in one group ($n = 6$) were vaccinated with p472 emulsified in CFA and rats in another group ($n = 6$) were injected with PBS only. Motor behavior was assessed weekly in an open field by observers blinded to the treatment received by the rat. Recovery was best in rats vaccinated with p472. Results are mean values of the motor score \pm SEM. Significance of the difference between the groups was determined by using a two-tailed Student's t test (*, $P < 0.05$; **, $P < 0.01$).

by the peptide-specific immunization was more pronounced than the CFA-induced boosting of the endogenous response. In the males, improvement in recovery after p472 immunization also was significant, although less substantial than in the females: behavioral scores were 5.1 ± 0.6 with p472 in CFA and 3.6 ± 0.2 with PBS in CFA (Fig. 2A). The better recovery in the female rats is in line with a recent finding from our laboratory (17). These two experiments raised a key question: how does the observed effect of the Nogo-A-derived peptide in reducing posttraumatic immunization compare with that of MBP-derived peptides?

We recently reported that active posttraumatic vaccination of rats with an MBP-derived peptide (p87–99; Ala-91) altered by one amino acid replacement (Lys-91 by Ala) leads to significant neuroprotection (17). Here, we compared the effects of Ala-91 and p472 (both emulsified in CFA). The results obtained with the peptide Ala-91 were better (Fig. 2B). The highest locomotor score obtained was 6.6 ± 0.6 in rats immunized with Ala-91 in CFA compared with 3.4 ± 0.7 in rats injected with PBS in CFA. These results, and the small differences between control values in the two experiments (Fig. 2A vs. B), indicate that both peptides are effective but do not permit definite conclusions about differences in their efficacy.

In a second set of experiments, SPD males with a milder contusive injury (caused by a weight drop from a height of 25 mm) were vaccinated with p472. As before, the effect was evident from day 14 on and was then significant at all times of assessment, according to a two-tailed Student's t test (Fig. 2C). The highest behavioral score in these rats was 8.9 ± 0.5 , compared with 7.0 ± 0.45 after vaccination with PBS in CFA.

The behavioral recovery scores of p472-immunized rats after a weight drop from 25 mm reached plateau values that exceeded the threshold values correlated with sparing of the rubrospinal tracts needed for weight support. To confirm that the better recovery seen in these rats is related to a better survival of the rubrospinal tracts, we compared the integrity of the rubrospinal tracts in p472-immunized rats and rats injected with CFA in PBS (Fig. 2C). In rats with a BBB score around 8 (indicative of weight support), retrograde labeling gave an "all-or-none" indication of




Fig. 2. Comparison between vaccination with the Nogo-derived peptide p472 and the MBP-derived altered peptide Ala-91 in male SPD rats. (A) Male SPD rats were subjected to spinal contusion as described for Fig. 1. Immediately after the contusion, the animals were randomly divided into two groups ($n = 6$ in each group). Rats in the first group were immunized with p472 in CFA, and rats in the second group were injected with PBS in CFA. Motor behavior was assessed as described for Fig. 1. Results are mean values of the motor score \pm SEM. (B) Male SPD rats were injured and grouped as in A and were immunized with Ala-91 in CFA or injected with PBS in CFA. Motor recovery in the Ala-91-treated group, assessed as in A, was at least as good as with p472 treatment. Results are mean values of the motor score \pm SEM. (C) Assessment of recovery from a milder spinal contusion inflicted by dropping the 10-g weight from a height of 25 mm (*, $P < 0.05$; **, $P < 0.01$).

rubrospinal tract survival (28–30). The examined control rats (average BBB score = 6.5 ± 0.5) showed almost no labeled red nuclei. In the examined p472-immunized rats (BBB score 9.4 ± 0.3 ; $n = 3$), 142 ± 46 red nuclei were labeled (Fig. 3).

To determine whether the immunity directed against Nogo-A




Fig. 4. Presence of proliferating T cells specific to p472 and absence of anti-p472 antibodies 1 week after vaccination with p472. (A) The proliferative response of splenocytes prepared from rats injected with p472 in CFA or with PBS in CFA to their specific antigen was compared with their proliferative response to the nonspecific antigen (OVA) in CFA or in the absence of antigen. Results are expressed as the mean cpm values of quadruplicate samples obtained from three different animals \pm SEM. (B) Antibodies in the treated rats were assayed by ELISA. The amount of antibodies detected in the rats immunized with p472 in CFA was not significantly greater than in those injected with PBS in CFA. Results are expressed by mean values (expressed in arbitrary units) \pm SEM obtained from three rats, each tested in triplicate at each of the indicated dilutions.

(yielding the improved recovery observed here) was of cellular or humoral origin, we examined the immunized rats for specific anti-p472 T cells in lymph nodes and for antibodies in the serum. T cell proliferation assay revealed proliferating T cells in rats immunized with p472 in CFA when tested with the p472-derived peptide. The same lymphocytes were incubated with MBP-derived peptide (87–99) or OVA as controls. No p472-specific T cells were found in control rats injected with PBS in CFA (Fig. 4A). Antibody assays revealed no significant differences in IgM antibody titer between the rats injected with p472 in CFA and those injected with PBS in CFA (Fig. 4B).

None of the immunized rats developed symptoms of EAE. Because SPD rats are resistant to EAE induction, we examined whether p472 immunization of the EAE-susceptible Lewis rats would induce the disease. No clear signs of EAE were observed. It is possible, however, that infiltrating Nogo-specific T cells caused silent clinical changes in the CNS, as reported with other myelin-derived autoantigens, for example, myelin-associated glycoprotein (31, 32).

T Cells Directed Against Nogo-A-Derived Peptide Are Neuroprotective When Passively Transferred into SPD Rats. The above results suggest that the neuroprotection observed after active vaccination with p472 is mediated by T cells specific to that peptide. To verify this




Fig. 5. Passive transfer of p472-specific T cells into spinally contused rats promotes recovery. Male SPD rats were subjected to spinal contusion as described for Fig. 1. Immediately after contusion, the rats were divided into two groups ($n = 5$ in each group). Rats in one group were injected intraperitoneally with p472-specific T cells (1×10^7 cells) in PBS, and rats in other groups were injected with PBS only. Motor behavior was assessed in an open field by observers blinded to the treatment received. Results are mean values of the motor score \pm SEM. Significance of the differences between the groups at each time point was determined by using a two-tailed Student's *t* test (*, $P < 0.05$).

suggestion, we prepared a T cell line specific to p472. Passive transfer of anti-p472 T cells after spinal contusion in rats had a protective effect, which became apparent as early as 8 days after the injury; the highest behavioral score was 6 ± 0.6 for rats treated with the T cells and 4 ± 0.5 for untreated controls (Fig. 5). The efficacy of different routes of immunization (active and passive; compare Fig. 2A and Fig. 5) should be compared with caution because of the difference in their numbers of available T cells at the lesion site during the therapeutic time window. Also, the efficacy of passive T-cell transfer is critically dependent on matching between the MHC-II characteristics of donor and recipient, meaning that inbred strains and homologous cells must be used. The SPD strain, although not inbred, is stably heterogeneous. It derives from a hybrid of Hooded males and Wistar females, with subsequent lines developed into a stable stock. The rats used in our studies were obtained from Harlan–Sprague–Dawley, and all were descended from the same original stock. We created a primary T cell line by *in vitro* propagation of lymphocytes from immunized SPD rats by using antigen-presenting cells (APCs) from other SPD rats. Thus, despite the heterogeneity, the rats evidently share enough homology in their expressed MHC-II for this purpose (for the *in vitro* propagation in this strain, we always used twice as many thymocytes as APCs than when working with inbred strains). Because of the heterogeneity, the passively transferred T cells might be less effective than in inbred rats using homologous cells; nevertheless, our results confirmed that the protection is mediated by T cells.

Immunization with Nogo-A Reduces Loss of RGCs After Optic-Nerve Injury. The posttraumatic loss of RGCs can be significantly reduced by passive transfer of T cells directed against myelin antigens or by active immunization with these antigens (12, 18, 19, 33). To determine whether active immunization is as effective with p472 as with other myelin antigens, we immunized SPD rats with p472 emulsified in CFA. Control injured rats were injected with PBS emulsified in CFA. When the rats were immunized before the insult, the number of surviving RGCs, determined by retrograde labeling 2 weeks after the insult, was significantly larger in the p472-immunized rats than in the




Fig. 6. Immunization with p472 reduces RGC loss after partial crush injury of the rat optic nerve. (A) Rats were subjected to a calibrated crush injury of the optic nerve immediately before or 5 days after injection with p472 in CFA, PBS in CFA, or T cells directed to p472. (B) Rats were immunized with Ala-91 in CFA or PBS in CFA immediately after optic-nerve crush. In both A and B, the optic nerves were re-exposed 2 weeks later, and a dye was injected distally to the primary lesion. After 5 days, the retinas were excised and whole-mounted, and the RGCs were counted by observers blinded to the treatment received by the rats. Results are expressed as the mean numbers of RGCs per mm² ± SEM.

controls (Fig. 6A). Passive transfer of p472-specific T cells immediately after the insult had a beneficial effect on recovery, like that seen in our studies with T cells that are specific to myelin peptides or crossreactive with Cop-1 (10, 18). Active immunization with Ala-91 immediately after optic-nerve injury (Fig.

6B), like passive transfer of the T cells specific to p472 (Fig. 6A), yielded a better RGC survival rate than that seen in the control (Fig. 6A and B). This finding suggests that both p472 and Ala-91 are potentially neuroprotective antigens, and that the possible difference in their immunogenicity is manifested by how promptly they induce a response. No such difference is observed when the T cells are passively transferred.

Discussion

Recovery from spinal-cord injury depends on the severity of the insult (location of injury and the number of spared neurons), the amount of secondary degeneration, the ability to regenerate, and the ability to activate local mechanisms of plasticity. Whereas the question of regeneration is still largely unsolved, much more is now known about neuroprotection in general, especially in the context of the spinal cord. In particular, it is now clear why neuronal degeneration continues to progress after the primary insult and how the damage is propagated.

The design of therapeutic strategies has been hampered by some apparent contradictions in the findings of research, especially concerning the question of whether the recovery process is advanced or impeded by inflammation (34, 35). Anti-inflammatory drugs were reported to be beneficial after spinal-cord injury, leading to the tentative conclusion that an inflammatory reaction is bad for recovery (36). However, recent studies (14, 37, 38) indicate that the adaptive immune response, which is spontaneously evoked by a spinal-cord injury, is beneficial for recovery in some strains, depending on their inherent susceptibility to EAE (15). The T cell-dependent protective autoimmunity was found to be characterized also by sexual dimorphism, with female rats recovering better than males after spinal-cord contusion (E.H. *et al.*, unpublished work). The injury-evoked, T cell-mediated protective response was found to be boosted in EAE-resistant strains (or induced in EAE-susceptible strains) by passive transfer of anti-MBP T cells or by active vaccination with certain myelin-associated self-antigens (17).

In this study, we show that a peptide derived from Nogo-A, a myelin component known to inhibit posttraumatic regeneration, can activate the immune system in a beneficial way. This peptide had a neuroprotective effect in the same model and with the same therapeutic time window as that shown by us to accommodate a T cell-based therapy (10). Thus, after partial crush injury of the rat optic nerve or spinal cord, prompt vaccination



Fig. 7. Retrograde labeling of cell bodies in the red nucleus. Three months after spinal contusion, rats from each group were reanesthetized, and the dye rhodamine dextran amine (Fluoro-ruby) was applied below the site of contusion. Five days later, the rats were killed, and their brains were excised, processed, and cryosectioned. Sections taken through the red nucleus were inspected and analyzed by fluorescence confocal microscopy. The photographs are of p472-immunized rats and of the control rats shown in Fig 2C.

(within 1 h after the injury) with Nogo-A-derived peptide emulsified in CFA evoked a T cell-mediated protective autoimmunity. Within this time window, we detected p472-specific T cells in the immunized injured rats, but no anti-p472 antibodies. Similar results were obtained after passive transfer of T cells specific to the Nogo-A-derived peptide. Therefore, we considered it important to determine whether a peptide derived from Nogo-A has advantages over other myelin-associated peptides as a potential vaccine. Based on the present comparison with the effect of an MBP-derived peptide, the answer is that it does not.

Recent studies reveal that, for protective autoimmunity, both autoimmune T cells and regulatory T cells are essential constituents of this network, but neither of them on its own suffices to bring about neuroprotection (39). When considering the use of a particular myelin-associated peptide for therapy, it is important to ascertain that the T cell response it elicits falls within the therapeutic window, and that it will confer the desired benefit without risking the development of an autoimmune disease. Also, such peptides should not elicit any immune activity that interferes with their essential physiological activities, if any. In susceptible rat strains, a modified encephalitogenic peptide was found to be beneficial (17). This study demonstrates that in EAE-susceptible rat strains, Nogo-A-derived peptides were not

encephalitogenic. However, we cannot rule out the possibility that vaccination with Nogo-A-derived peptides might evoke, in addition to the observed T cell response, a delayed antibody response. Although apparently not needed for neuroprotection, these antibodies might interfere with the essential activities of Nogo-A in maintaining the integrity of the adult CNS. Such interference might be a potential side effect of the use of anti-Nogo-A antibodies for regeneration (26). In view of this possible drawback, it might be preferable to choose a myelin-associated peptide that does not play a role in neuronal plasticity. Alternatively, it might be possible to exploit the neuroprotective property of Nogo-derived peptides in a way that avoids the appearance of antibodies by using passive vaccination with anti-Nogo T cells rather than active immunization with the peptides themselves.

T cell-mediated active or passive vaccination is a promising treatment for posttraumatic treatment of the injured spinal cord, because it is based on harnessing the immune system. Because the active players are immune cells and not antibodies, this type of therapy is likely to provide multifactorial protection.

We thank S. Smith for editing the manuscript. M.S. holds the Maurice and Ilse Katz Professorial Chair in Neuroimmunology. The work was supported in part by Proneuron Biotechnologies, Ltd., Israel.

- Schwab, M. E. & Bartholdi, D. (1996) *Physiol. Rev.* **76**, 319–370.
- Bandtlow, C. E. & Schwab, M. E. (2000) *Glia* **29**, 175–181.
- Brittis, P. A. & Flanagan, J. G. (2001) *Neuron* **30**, 11–14.
- Fournier, A. E. & Strittmatter, S. M. (2001) *Curr. Opin. Neurobiol.* **11**, 89–94.
- Huber, A. B. & Schwab, M. E. (2000) *Biol. Chem. Hoppe-Seyler* **381**, 407–419.
- Qiu, J., Cai, D. & Filbin, M. T. (2000) *Glia* **29**, 166–174.
- Chen, M. S., Huber, A. B., van der Haar, M. E., Frank, M., Schnell, L., Spillmann, A. A., Christ, F. & Schwab, M. E. (2000) *Nature (London)* **403**, 434–439.
- Bregman, B. S., Kunkel-Bagden, E., Schnell, L., Dai, H. N., Gao, D. & Schwab, M. E. (1995) *Nature (London)* **378**, 498–501.
- Brosamle, C., Huber, A. B., Fiedler, M., Skerra, A. & Schwab, M. E. (2000) *J. Neurosci.* **20**, 8061–8068.
- Hauben, E., Butovsky, O., Nevo, U., Yoles, E., Moalem, G., Agranov, E., Mor, F., Leibowitz-Amit, R., Pevsner, E., Akselrod, S., et al. (2000) *J. Neurosci.* **20**, 6421–6430.
- Lazarov-Spiegler, O., Solomon, A. S., Zeev-Brann, A. B., Hirschberg, D. L., Lavie, V. & Schwartz, M. (1996) *FASEB J.* **10**, 1296–1302.
- Moalem, G., Leibowitz-Amit, R., Yoles, E., Mor, F., Cohen, I. R. & Schwartz, M. (1999) *Nat. Med.* **5**, 49–55.
- Rapalino, O., Lazarov-Spiegler, O., Agranov, E., Velan, G. J., Yoles, E., Fraidakis, M., Solomon, A., Gepstein, R., Katz, A., Belkin, M., et al. (1998) *Nat. Med.* **4**, 814–821.
- Yoles, E., Hauben, E., Palgi, O., Agranov, E., Gothilf, A., Cohen, A., Kuchroo, V., Cohen, I. R., Weiner, H. & Schwartz, M. (2001) *J. Neurosci.* **21**, 3740–3748.
- Kipnis, J., Yoles, E., Schori, H., Hauben, E., Shaked, I. & Schwartz, M. (2001) *J. Neurosci.* **21**, 4564–4571.
- Hauben, E., Nevo, U., Yoles, E., Moalem, G., Agranov, E., Mor, F., Akselrod, S., Neeman, M., Cohen, I. R. & Schwartz, M. (2000) *Lancet* **355**, 286–287.
- Hauben, E., Agranov, E., Gothilf, A., Nevo, U., Cohen, A., Smirnov, I., Steinman, L. & Schwartz, M. (2001) *J. Clin. Invest.* **108**, 591–599.
- Kipnis, J., Yoles, E., Porat, Z., Cohen, A., Mor, F., Sela, M., Cohen, I. R. & Schwartz, M. (2000) *Proc. Natl. Acad. Sci. USA* **97**, 7446–7451.
- Schori, H., Kipnis, J., Yoles, E., WoldeMussie, E., Ruiz, G., Wheeler, L. A. & Schwartz, M. (2001) *Proc. Natl. Acad. Sci. USA* **98**, 3398–3403. (First Published March 6, 2001; 10.1073/pnas.041609498)
- Gaur, A., Boehme, S. A., Chalmers, D., Crowe, P. D., Pahuja, A., Ling, N., Brocke, S., Steinman, L. & Conlon, P. J. (1997) *J. Neuroimmunol.* **74**, 149–158.
- Young, W. (1996) *Science* **273**, 451.
- Ben-Nun, A. & Cohen, I. R. (1982) *J. Immunol.* **129**, 303–308.
- Gillis, S., Ferm, M. M., Ou, W. & Smith, K. A. (1978) *J. Immunol.* **120**, 2027–2032.
- Basso, D. M., Beattie, M. S. & Bresnahan, J. C. (1996) *Exp. Neurol.* **139**, 244–256.
- Yoles, E. & Schwartz, M. (1998) *Exp. Neurol.* **153**, 1–7.
- Raineteau, O., Fouad, K., Noth, P., Thallmair, M. & Schwab, M. E. (2001) *Proc. Natl. Acad. Sci. USA* **98**, 6929–6934. (First Published May 29, 2001; 10.1073/pnas.111165498)
- Merkler, D., Metz, G. A. S., Raineteau, O., Dietz, V., Schwab, M. E. & Fouad, K. (2001) *J. Neurosci.* **21**, 3665–3673.
- Fehlings, M. G. & Tator, C. H. (1995) *Exp. Neurol.* **132**, 220–228.
- Midha, R., Fehlings, M. G., Tator, C. H., Saint-Cyr, J. A. & Guha, A. (1987) *Brain Res.* **410**, 299–308.
- Theriault, E. & Tator, C. H. (1994) *J. Comp. Neurol.* **342**, 249–258.
- Weerth, S., Berger, T., Lassmann, H. & Linington, C. (1999) *J. Neuroimmunol.* **95**, 157–164.
- Linington, C., Berger, T., Perry, L., Weerth, S., Hinze-Selch, D., Zhang, Y., Lu, H. C., Lassmann, H. & Wekerle, H. (1993) *Eur. J. Immunol.* **23**, 1364–1372.
- Fisher, J., Yoles, E., Levkovitch-Verbin, H., Kaye, J. F., Ben-Nun, A. & Schwartz, M. (2001) *J. Neurosci.* **21**, 136–142.
- Bethea, J. R., Nagashima, H., Acosta, M. C., Briceno, C., Gomez, F., Marcillo, A. E., Loo, K., Green, J. & Dietrich, W. D. (1999) *J. Neurotrauma* **16**, 851–863.
- Bethea, J. R. (2000) *Prog. Brain Res.* **128**, 33–42.
- Mautes, A. E., Weinzierl, M. R., Donovan, F. & Noble, L. J. (2000) *Phys. Ther.* **80**, 673–687.
- Serpe, C. J., Kohm, A. P., Huppenbauer, C. B., Sanders, V. M. & Jones, K. J. (1999) *J. Neurosci.* **19**, RC7.
- Serpe, C. J., Sanders, V. M. & Jones, K. J. (2000) *J. Neurosci. Res.* **62**, 273–278.
- Schwab, M. & Kipnis, J. (2001) *Trends Mol. Med.* **7**, 252–258.